How this is applied.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889450/
Here is the Research
AnnMovDisord3139-7482209_204702.pdf (191.9 KB)
published in 2020
A total of 50 members completed the survey (20%) representing different regions of the
country. The average doses of botulinum toxin conform to those mentioned in the literature. Only
type A botulinum toxin is available in India. Electromyography was used by 72% of the respondents,
however, only 12% of respondents used ultrasonography for muscle localization during botulinum
toxin injection. 72% of respondents were using an assessment scale for different types of movement
disorders. 76% of the respondents reported adverse effects in their clinical practice, with weakness
(69.11%) being the most common. 56% of the respondents reported challenges during the injections
with the cost of botulinum toxin being the most common (36%) followed by difficulty in localization
of muscles (30%).
CONCLUSION: Our results seem to show that in India, the routine use of botulinum toxin in clinics
is far from standardized. Low uses of USG, difficulty in muscle localization and cost of the toxin were
important limitations highlighted by the respondents.
Another Research Paper on usage of Botulinum in Cosmetology (Anti-Aging )
It is a deadly medicine (this is what I understand so far ), if it is such niche and has some decent market share then
- Why there no big players in the market entered ? It appears to be Amgen is the largest player in this
- As per Dr. Hitesh this is widely used, there are many different application of this molecule for different treatments. What Gufic is trying is to address the Cosmetology side application. (This is what they said in the IP )
Some more we can extract from the con-call transcript
Some more info at the time stamps given below during Q2FY22 concall
Indian Market Size is 120 Crore at the moment (Potential is huge in India and wanted to enter into international market as well but it is not easy )
Going to setup training committee to educate
Experts coming from Germany, US and UK (this calendar year first and second quarter going to roadshows to create more awareness )
18:39
49:00
Gland is one of the strong player in Penems , Gufic at the momentum they are outsourcing at the moment, they are going to backward integrate now . Margins will go up once they start producing in-house by at least by 10%
Other Players in Penems
Aurobindo Pharma
Morepen Laboratories
Gland Pharma
Dr Reddy’s Laboratories
Caplin Point Laboratories
Strides Pharma Science
- One strong segment is Injectables, this area is not that much price sensitive (Less price erosion in US market )